Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Short-Term Effect of Hypergastrinemia Following Esomeprazole Treatment On Well-Controlled Type 2 Diabetes Mellitus: A Prospective Study

Author(s): Yusuf Bozkuş*, Umut Mousa, Özlem T. İyidir, Nazlı Kırnap, Canan Ç. Demir, Aslı Nar and Neslihan B. Tütüncü

Volume 20, Issue 7, 2020

Page: [1090 - 1096] Pages: 7

DOI: 10.2174/1871530320666200129124555

Price: $65

Abstract

Objective: Proton pump inhibitor (PPI) drugs reduce gastric acid secretion and lead to an increase in serum gastrin levels. Many preclinical and some clinical researches have established some positive effects of gastrin or PPI therapy on glucose regulation. The aim of this study was to prospectively investigate the short term effects of esomeprazole on glycaemic control in patients with type 2 diabetes mellitus. In addition, the presence of an association between this effect and gastrin levels was evaluated.

Methods: Thirty-two subjects with type 2 diabetes mellitus were enrolled and grouped as intervention (n=16) and control (n=16). The participants in the intervention group were prescribed 40 mg of esomeprazole treatment for three months. At the beginning of the study and at the 3rd month, HbA1c level (%) and gastrin levels (pmol/L) of participants were assessed. Then, the groups were compared in terms of their baseline and 3rd month values.

Results: In the intervention group, the mean gastrin level increased significantly from 34.3±14.4 pmol/L to 87.4±43.6 pmol/L (p<0.001). The mean HbA1c level was similar to the pre-treatment level (6.3±0.7% vs. 6.4±0.9%, p=0.441). There were no statistically significant differences in all parameters of the control group. The majority of individuals were on metformin monotherapy (65.6 %). The subgroup analysis of metformin monotherapy revealed that, in intervention group, there was a significant increase in gastrin levels (39.9±12.6 vs. 95.5±52.5, p=0.026), but the HbA1c levels did not change (6.0±0.4 % vs. 5.9±0.6 %, p=0.288); and in control group, gastrin levels did not change (37.5 ± 26.7 vs. 36.1 ±23.3, p=0.367), but there was an increase in HbA1c levels (6.1 ± 0.50 vs. 6.4 ± 0.60, p=0.01).

Conclusion: Our study demonstrates that esomeprazole has no extra benefit for the controlled diabetic patient in three months. However, in only the metformin-treated subgroup, esomeprazole may prevent the rise in HbA1c level.

Keywords: Esomeprazole, gastrin, HbA1c, type 2 diabetes, diabetes treatment, incretin.

« Previous Next »
Graphical Abstract

[1]
Cadiot, G.; Vissuzaine, C.; Pospai, D.; Ruszniewski, P.; Potet, F.; Mignon, M. Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results. Gastroenterol. Clin. Biol., 1995, 19(10), 811-817.
[PMID: 8566561]
[2]
Esplugues, J.V.; Martí-Cabrera, M.; Ponce, J. [Safety of proton pump inhibitors] Med. Clin. (Barc.), 2006, 127(20), 790-795.
[http://dx.doi.org/10.1157/13095825] [PMID: 17198667]
[3]
Brand, S.J.; Tagerud, S.; Lambert, P.; Magil, S.G.; Tatarkiewicz, K.; Doiron, K.; Yan, Y. Pharmacological treatment of chronic diabetes by stimulating pancreatic β-cell regeneration with systemic co-administration of EGF and gastrin. Pharmacol. Toxicol., 2002, 91(6), 414-420.
[http://dx.doi.org/10.1034/j.1600-0773.2002.910621.x] [PMID: 12688387]
[4]
Rehfeld, J.F.; Stadil, F. The effect of gastrin on basal- and glucose-stimulated insulin secretion in man. J. Clin. Invest., 1973, 52(6), 1415-1426.
[http://dx.doi.org/10.1172/JCI107315] [PMID: 4703228]
[5]
Rooman, I.; Lardon, J.; Bouwens, L. Gastrin stimulates beta-cell neogenesis and increases islet mass from transdifferentiated but not from normal exocrine pancreas tissue. Diabetes, 2002, 51(3), 686-690.
[http://dx.doi.org/10.2337/diabetes.51.3.686] [PMID: 11872667]
[6]
Bödvarsdóttir, T.B.; Hove, K.D.; Gotfredsen, C.F.; Pridal, L.; Vaag, A.; Karlsen, A.E.; Petersen, J.S. Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia, 2010, 53(10), 2220-2223.
[http://dx.doi.org/10.1007/s00125-010-1825-6] [PMID: 20585936]
[7]
Meier, J.J.; Butler, A.E.; Galasso, R.; Rizza, R.A.; Butler, P.C. Increased islet beta cell replication adjacent to intrapancreatic gastrinomas in humans. Diabetologia, 2006, 49(11), 2689-2696.
[http://dx.doi.org/10.1007/s00125-006-0410-5] [PMID: 17016695]
[8]
Zollinger, R.M.; Ellison, E.H. Primary peptic ulcerations of the jejunum associated with islet cell tumors of the pancreas. Ann. Surg., 1955, 142(4), 709-723.
[http://dx.doi.org/10.1097/00000658-195510000-00015] [PMID: 13259432]
[9]
Suarez-Pinzon, W.L.; Power, R.F.; Yan, Y.; Wasserfall, C.; Atkinson, M.; Rabinovitch, A. Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes, 2008, 57(12), 3281-3288.
[http://dx.doi.org/10.2337/db08-0688] [PMID: 18835930]
[10]
Suarez-Pinzon, W.L.; Cembrowski, G.S.; Rabinovitch, A. Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia, 2009, 52(8), 1680-1682.
[http://dx.doi.org/10.1007/s00125-009-1390-z] [PMID: 19455306]
[11]
Mefford, I.N.; Wade, E.U. Proton pump inhibitors as a treatment method for type II diabetes. Med. Hypotheses, 2009, 73(1), 29-32.
[http://dx.doi.org/10.1016/j.mehy.2009.02.010] [PMID: 19304401]
[12]
Hove, K.D.; Færch, K.; Bödvarsdóttir, T.B.; Karlsen, A.E.; Petersen, J.S.; Vaag, A. Treatment with a proton pump inhibitor improves glycaemic control in type 2 diabetic patients - a retrospective analysis. Diabetes Res. Clin. Pract., 2010, 90(3), e72-e74.
[http://dx.doi.org/10.1016/j.diabres.2010.09.007] [PMID: 20888658]
[13]
Boj-Carceller, D.; Bocos-Terraz, P.; Moreno-Vernis, M.; Sanz-Paris, A.; Trincado-Aznar, P.; Albero-Gamboa, R. Are proton pump inhibitors a new antidiabetic drug? A cross sectional study. World J. Diabetes, 2011, 2(12), 217-220.
[http://dx.doi.org/10.4239/wjd.v2.i12.217] [PMID: 22174957]
[14]
Crouch, M.A.; Mefford, I.N.; Wade, E.U. Proton pump inhibitor therapy associated with lower glycosylated hemoglobin levels in type 2 diabetes. J. Am. Board Fam. Med., 2012, 25(1), 50-54.
[http://dx.doi.org/10.3122/jabfm.2012.01.100161] [PMID: 22218624]
[15]
Han, N.; Oh, M.; Park, S.M.; Kim, Y.J.; Lee, E.J.; Kim, T.K.; Kim, T.N.; Kwon, M.J.; Kim, M.K.; Lee, S.H.; Rhee, B.D.; Park, J.H. The effect of proton pump inhibitors on glycated hemoglobin levels in patients with type 2 diabetes mellitus. Can. J. Diabetes, 2015, 39(1), 24-28.
[http://dx.doi.org/10.1016/j.jcjd.2013.10.008] [PMID: 25305802]
[16]
Barchetta, I.; Guglielmi, C.; Bertoccini, L.; Calella, D.; Manfrini, S.; Secchi, C.; Pozzilli, P.; Cavallo, M.G. IMDIAB group. Therapy with proton pump inhibitors in patients with type 2 diabetes is independently associated with improved glycometabolic control. Acta Diabetol., 2015, 52(5), 873-880.
[http://dx.doi.org/10.1007/s00592-015-0721-4] [PMID: 25716766]
[17]
Villegas, K.; Meier, J.L.; Long, M.; Lopez, J.; Swislocki, A. The Effect of Proton Pump Inhibitors on Glycemic Control in Patients with Type 2 Diabetes. Metab. Syndr. Relat. Disord., 2019, 17(4), 192-196.
[http://dx.doi.org/10.1089/met.2018.0138] [PMID: 30730235]
[18]
Singh, P.K.; Hota, D.; Dutta, P.; Sachdeva, N.; Chakrabarti, A.; Srinivasan, A.; Singh, I.; Bhansali, A. Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab., 2012, 97(11), E2105-E2108.
[http://dx.doi.org/10.1210/jc.2012-1720] [PMID: 22904177]
[19]
Hove, K.D.; Brøns, C.; Færch, K.; Lund, S.S.; Petersen, J.S.; Karlsen, A.E.; Rossing, P.; Rehfeld, J.F.; Vaag, A. Effects of 12 weeks’ treatment with a proton pump inhibitor on insulin secretion, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind prospective placebo-controlled study. Diabetologia, 2013, 56(1), 22-30.
[http://dx.doi.org/10.1007/s00125-012-2714-y] [PMID: 23011351]
[20]
Takebayashi, K.; Sakurai, S.; Suzuki, T.; Hori, K.; Terasawa, T.; Naruse, R.; Hara, K.; Suetsugu, M.; Tsuchiya, T.; Aoki, H.; Hamasaki, T.; Shuutou, H.; Inukai, T. Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes. Endocr. J., 2014, 61(10), 1031-1039.
[http://dx.doi.org/10.1507/endocrj.EJ14-0208] [PMID: 25185672]
[21]
González-Ortiz, M.; Martínez-Abundis, E.; Mercado-Sesma, A.R.; Álvarez-Carrillo, R. Effect of pantoprazole on insulin secretion in drug-naïve patients with type 2 diabetes. Diabetes Res. Clin. Pract., 2015, 108(1), e11-e13.
[http://dx.doi.org/10.1016/j.diabres.2015.01.039] [PMID: 25704601]
[22]
Gorji, H.M.; Gorji, N.M.; Vasel, A.; Rahimi, B. The effect of proton pump inhibitors on glycemic control in patients with type II diabetes. J Clin Anal Med., 2017, 8(Suppl. 5), 504-508.
[23]
Gómez-Izquierdo, J.C.; Yu, O.H.Y. The Influence of Proton-Pump Inhibitors on Glycemic Control: A Systematic Review of the Literature and a Meta-Analysis. Can. J. Diabetes, 2017, 41(4), 351-361.
[http://dx.doi.org/10.1016/j.jcjd.2016.11.004] [PMID: 28373033]
[24]
Takebayashi, K.; Inukai, T. Effect of proton pump inhibitors on glycemic control in patients with diabetes. World J. Diabetes, 2015, 6(10), 1122-1131.
[http://dx.doi.org/10.4239/wjd.v6.i10.1122] [PMID: 26322158]
[25]
Chaudhury, A.; Duvoor, C.; Reddy Dendi, V.S.; Kraleti, S.; Chada, A.; Ravilla, R.; Marco, A.; Shekhawat, N.S.; Montales, M.T.; Kuriakose, K.; Sasapu, A.; Beebe, A.; Patil, N.; Musham, C.K.; Lohani, G.P.; Mirza, W. Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management Review Article. Front. Endocrinol. (Lausanne), 2017, 8(6), 1-12.
[http://dx.doi.org/10.3389/fendo.2017.00006]

Rights & Permissions Print Cite
Article Metrics
11
© 2024 Bentham Science Publishers | Privacy Policy